Arcus Biosciences, Inc. (RCUS) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-25
Business type: Asset play
How it makes money
It generates revenue by selling access to its pipeline through $100 million continuation payments and $150 million option fees from partner Gilead.
The company has not yet generated any revenue from product sales. Instead, it relies on strategic partners to fund development in exchange for commercial rights. Gilead pays $100 million annual continuation fees and $150 million per program to exercise options on molecules like domvanalimab and quemliclustat.
For optioned programs, it shares U.S. profits and losses equally with Gilead while receiving tiered royalties ranging from high teens to low twenties on sales outside the U.S. Taiho pays between $3 million to $15 million per option exercise for specific Asian territories.
What protects it: the moat
It relies on a patent estate of 850 pending or issued patents and exclusive collaboration agreements with Gilead and Taiho.
Management claims its competitive advantage is derived from an internal small-molecule discovery infrastructure that produces differentiated therapies like casdatifan. These assets are protected by composition-of-matter patents projected to expire between 2036 and 2045, legally preventing rivals from replicating its molecular designs.
Furthermore, its collaboration agreements grant it U.S. co-promotion rights and established funding streams, creating a high barrier for competitors attempting to outspend it in late-stage clinical development.
What growth costs
It prioritizes its $1.0 billion in cash toward advancing late-stage clinical trials for casdatifan and its small-molecule inflammation programs.
The company must spend heavily on R&D to advance its molecules through Phase 3 registrational studies, which are capital-intensive. It maintains $1.0 billion in liquid assets to fund operations until 2028, reflecting the high costs of trials like PEAK-1 and PRISM-1.
To manage these costs, it selectively pauses lower-priority programs, such as etrumadenant, to focus reinvestment on casdatifan, which it solely owns globally. It also carries $100 million in drawn debt under a secured facility with Hercules Capital to provide additional liquidity.
What could damage it
The discontinuation of the STAR-221 trial due to futility illustrates how clinical failures permanently destroy the value of its primary licensing programs.
Earnings are entirely dependent on the successful clinical outcome of its drug candidates. If a molecule fails to meet its primary endpoints, such as overall survival in cancer patients, partners like Gilead may decline to exercise options or pay milestones.
In December 2025, the independent monitoring committee recommended stopping the STAR-221 study for gastrointestinal cancer because it did not improve survival. Such failures stop the causal chain of milestone payments and future royalties that the company's valuation depends on.
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.